Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023
October 31, 2023 06:30 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023....
FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label
September 25, 2023 16:09 ET
|
Liquidia Corporation
Sets PDUFA goal date of January 24, 2024If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD MORRISVILLE, N.C., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation...
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office
September 06, 2023 16:30 ET
|
Liquidia Corporation
Asserts ‘793 patent in new litigation filed under Hatch-Waxman Act in response to Liquidia’s amendment to its NDA to add PH-ILD to YUTREPIA™ labelLitigation is tied to same ‘793 patent previously...
Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023 06:00 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the second quarter ended June 30, 2023. The...
Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023
August 03, 2023 08:17 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2023 financial results on Thursday, August 10, 2023....
Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder
July 27, 2023 06:00 ET
|
Liquidia Corporation
No new clinical data is required to add PH-ILD indication as per FDA correspondenceRecertified that YUTREPIA does not infringe any valid patents listed in the Orange Book for TyvasoPreparing for...
U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation
July 24, 2023 13:46 ET
|
Liquidia Corporation
Infringement case now only focused on ‘793 patent, previously found to be invalid by PTAB in IPRFederal Circuit expected to hear appeal of PTAB decision in late 4th quarter 2023 to early 2024If PTAB...
Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America
June 28, 2023 05:36 ET
|
Liquidia Corporation
Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil administered twice-daily with a short duration, next-generation nebulizerLiquidia funds $10 million...
Liquidia Corporation to Present at the 2023 Jefferies Healthcare Conference
May 31, 2023 06:30 ET
|
Liquidia Corporation
MORRISVILLE, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that Mr. Roger Jeffs, Chief Executive Officer, and Mr. Michael Kaseta, Chief...
Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference
May 19, 2023 06:15 ET
|
Liquidia Corporation
MORRISVILLE, N.C., May 19, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the Company will present data related to the investigational use...